{"id":"low-dose-ticagrelor","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Ventricular pauses"}]},"_chembl":{"chemblId":"CHEMBL398435","moleculeType":"Small molecule","molecularWeight":"522.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist that blocks ADP-induced platelet activation more rapidly and potently than other P2Y12 inhibitors. At lower doses, it maintains antiplatelet efficacy while potentially reducing bleeding risk compared to standard dosing. The drug is used to prevent thrombotic cardiovascular events in acute coronary syndromes and other high-risk populations.","oneSentence":"Low-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:21.522Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Secondary prevention of thrombotic cardiovascular events"}]},"trialDetails":[{"nctId":"NCT05047172","phase":"PHASE3","title":"Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-08-02","conditions":"Intracranial Arteriosclerosis, Stroke","enrollment":1683},{"nctId":"NCT06543082","phase":"PHASE4","title":"MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study","status":"RECRUITING","sponsor":"CHA University","startDate":"2024-08-05","conditions":"Acute Coronary Syndrome","enrollment":490},{"nctId":"NCT06228456","phase":"PHASE4","title":"Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-04-01","conditions":"Coronary Artery Disease","enrollment":50},{"nctId":"NCT05997693","phase":"PHASE3","title":"One-Month DAPT in CABG Patients","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-08-15","conditions":"Chronic Coronary Disease","enrollment":700},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT05476991","phase":"PHASE3","title":"Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-05-17","conditions":"Stroke, Stroke, Ischemic, Atherosclerosis","enrollment":2800},{"nctId":"NCT07080684","phase":"PHASE4","title":"Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Messina","startDate":"2025-12-01","conditions":"Chronic Coronary Syndrome","enrollment":1000},{"nctId":"NCT03465644","phase":"PHASE4","title":"TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI","status":"COMPLETED","sponsor":"Duk-Woo Park, MD","startDate":"2019-02-12","conditions":"Coronary Stenoses","enrollment":2018},{"nctId":"NCT06759272","phase":"PHASE4","title":"Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients","status":"NOT_YET_RECRUITING","sponsor":"Nur Hafizah Annezah binti Utuh","startDate":"2025-02","conditions":"Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome), SCAD","enrollment":120},{"nctId":"NCT06756945","phase":"PHASE4","title":"Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-01","conditions":"ST-elevation Myocardial Infarction (STEMI)","enrollment":3612},{"nctId":"NCT04505774","phase":"PHASE4","title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE","status":"COMPLETED","sponsor":"Matthew Neal MD","startDate":"2020-09-04","conditions":"Covid19","enrollment":3591},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04240834","phase":"PHASE4","title":"Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2021-02-01","conditions":"Acute Coronary Syndrome, Interventional Cardiology","enrollment":1220},{"nctId":"NCT04307511","phase":"PHASE4","title":"A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients","status":"RECRUITING","sponsor":"Shanghai Tong Ren Hospital","startDate":"2020-04-20","conditions":"Acute Coronary Syndrome Patients With Diabetes After PCI","enrollment":40},{"nctId":"NCT06254391","phase":"PHASE2","title":"Aspirin Dose Comparison in Elderly PCI Patients: 30mg vs. 75mg in Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2023-07-03","conditions":"Myocardial Infarction, Acute Coronary Syndrome","enrollment":40},{"nctId":"NCT04255602","phase":"PHASE4","title":"A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients","status":"UNKNOWN","sponsor":"Shanghai Tong Ren Hospital","startDate":"2020-02-19","conditions":"Acute Coronary Syndrome, Coronary Stent Implantation","enrollment":2120},{"nctId":"NCT04307485","phase":"PHASE4","title":"A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients","status":"UNKNOWN","sponsor":"Shanghai Tong Ren Hospital","startDate":"2020-03-10","conditions":"Senior Acute Coronary Syndrome Patients After PCI","enrollment":40},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT05831462","phase":"PHASE1, PHASE2","title":"De-escalation of Ticagrelor in Post PPCI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-06-01","conditions":"Ticagrelor","enrollment":400},{"nctId":"NCT04718025","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2022-02-07","conditions":"STEMI, NSTEMI, Unstable Angina","enrollment":4500},{"nctId":"NCT05746416","phase":"","title":"Xience Registry In Complex Lesion of Acute Coronary Syndrome Patients witH Ticagrelor (RICH)","status":"COMPLETED","sponsor":"Hanyang University Seoul Hospital","startDate":"2019-01-02","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome","enrollment":977},{"nctId":"NCT04739384","phase":"PHASE3","title":"Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS","status":"COMPLETED","sponsor":"Federico II University","startDate":"2021-04-01","conditions":"Acute Coronary Syndrome, STEMI, NSTEMI","enrollment":50},{"nctId":"NCT03718429","phase":"PHASE4","title":"Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-14","conditions":"Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation","enrollment":86},{"nctId":"NCT02539160","phase":"PHASE4","title":"Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-02","conditions":"Coronary Artery Disease, Diabetes Mellitus","enrollment":101},{"nctId":"NCT03679091","phase":"PHASE4","title":"Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.","status":"COMPLETED","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2018-08-29","conditions":"Platelet Reactivity","enrollment":36},{"nctId":"NCT03437044","phase":"PHASE4","title":"Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-03-14","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease","enrollment":40},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT01740479","phase":"NA","title":"Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Early PCI for STEMI","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2013-02-01","conditions":"Acute Myocardial Infarction, Coronary Artery Disease","enrollment":4042},{"nctId":"NCT02615704","phase":"","title":"\"Me and My Heart\" Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-02-11","conditions":"Acute Coronary Syndrome","enrollment":677},{"nctId":"NCT04206176","phase":"PHASE1, PHASE2","title":"The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease","status":"COMPLETED","sponsor":"The University of The West Indies","startDate":"2019-10-01","conditions":"Platelet Dysfunction Due to Drugs","enrollment":25},{"nctId":"NCT02925923","phase":"PHASE2","title":"Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2016-11-01","conditions":"Acute Coronary Syndrome, Angina, Unstable","enrollment":100},{"nctId":"NCT02247128","phase":"PHASE4","title":"Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2014-01","conditions":"Aortic Valve Disease, Myocardial Infarction, Stroke","enrollment":1016},{"nctId":"NCT04069234","phase":"PHASE3","title":"Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.","status":"WITHDRAWN","sponsor":"Region Skane","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Microvascular Coronary Artery Disease","enrollment":""},{"nctId":"NCT03775746","phase":"PHASE4","title":"Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS","status":"UNKNOWN","sponsor":"East and North Hertfordshire NHS Trust","startDate":"2019-01-08","conditions":"Acute Coronary Syndrome","enrollment":150},{"nctId":"NCT03381742","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Low-dose Ticagrelor","status":"COMPLETED","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2017-12-13","conditions":"Coronary Artery Disease","enrollment":3043},{"nctId":"NCT03387826","phase":"PHASE4","title":"Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction","status":"COMPLETED","sponsor":"Attikon Hospital","startDate":"2018-01-11","conditions":"Myocardial Infarction, Diabetes Mellitus, Coronary Artery Disease","enrollment":20},{"nctId":"NCT03620760","phase":"PHASE4","title":"Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation","status":"UNKNOWN","sponsor":"Xiaofan Wu","startDate":"2018-08-07","conditions":"Unstable Angina Pectoris, Coronary Stent Implantation","enrollment":2036},{"nctId":"NCT03381755","phase":"PHASE4","title":"Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2018-01-01","conditions":"Acute Coronary Syndrome","enrollment":200},{"nctId":"NCT03614832","phase":"PHASE4","title":"Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2018-05-01","conditions":"Platelet Reactivity","enrollment":100},{"nctId":"NCT03184805","phase":"NA","title":"STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation","status":"TERMINATED","sponsor":"Yonsei University","startDate":"2017-06-23","conditions":"Coronary Artery Disease","enrollment":140},{"nctId":"NCT03441412","phase":"PHASE1","title":"A Study of the Effect of Epinephrine on Platelet Reactivity in Subjects Treated With Ticagrelor","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2018-02-28","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT03062462","phase":"PHASE2, PHASE3","title":"Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2017-02-10","conditions":"Coronary Artery Disease, Clopidogrel, Poor Metabolism of","enrollment":80},{"nctId":"NCT03481257","phase":"","title":"Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2017-04-12","conditions":"Acute Coronary Syndrome, Acute Myocardial Infarction, Unstable Angina","enrollment":56},{"nctId":"NCT01830543","phase":"PHASE3","title":"A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-05-10","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2124},{"nctId":"NCT02663713","phase":"PHASE4","title":"A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction","status":"COMPLETED","sponsor":"University of Patras","startDate":"2017-01","conditions":"Myocardial Infarction, Diabetes Mellitus, Renal Disease","enrollment":20},{"nctId":"NCT02319941","phase":"PHASE2","title":"Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes","status":"COMPLETED","sponsor":"Seung-Jung Park","startDate":"2015-05-20","conditions":"Acute Coronary Syndrome","enrollment":65},{"nctId":"NCT02064985","phase":"PHASE4","title":"Ticagrelor China Pharmacokinetic/Pharmacodynamic Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-02","conditions":"Stable Coronary Heart Disease (CHD)","enrollment":61},{"nctId":"NCT02514642","phase":"PHASE4","title":"Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2015-07","conditions":"Coronary Artery Disease","enrollment":30},{"nctId":"NCT02415803","phase":"PHASE3","title":"Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2014-12","conditions":"Non ST Segment Elevation Acute Coronary Syndrome","enrollment":75},{"nctId":"NCT02080858","phase":"PHASE1","title":"Triple vs. Dual Therapy","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2014-05","conditions":"Atrial Fibrillation, Acute Coronary Syndrome","enrollment":40},{"nctId":"NCT02406911","phase":"PHASE3","title":"Ticagrelor and Anti-inflammatory Effects","status":"UNKNOWN","sponsor":"Kyunghee University Medical Center","startDate":"2015-02","conditions":"Chronic Kidney Disease","enrollment":25},{"nctId":"NCT01118325","phase":"PHASE2","title":"An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-04","conditions":"Stable Coronary Artery Disease","enrollment":146},{"nctId":"NCT01294462","phase":"PHASE3","title":"Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-02","conditions":"Acute Coronary Syndrome, Percutaneous Coronary Intervention","enrollment":801},{"nctId":"NCT01456364","phase":"PHASE4","title":"Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing","status":"UNKNOWN","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2011-09","conditions":"Coronary Heart Disease","enrollment":70},{"nctId":"NCT01595854","phase":"PHASE1","title":"Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-05","conditions":"Healthy","enrollment":36},{"nctId":"NCT01643031","phase":"PHASE4","title":"Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2012-08","conditions":"Diabetes Mellitus, Coronary Disease","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["low-dose ticagrelor(22.5 mg twice daily)"],"phase":"marketed","status":"active","brandName":"low-dose ticagrelor","genericName":"low-dose ticagrelor","companyName":"First Affiliated Hospital of Harbin Medical University","companyId":"first-affiliated-hospital-of-harbin-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events. Used for Acute coronary syndrome, Secondary prevention of thrombotic cardiovascular events.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}